- Home
- WTTR vs GHRS Comparison
WTTR vs GHRS Comparison
Compare WTTR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WTTR | GHRS |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WTTR | GHRS |
|---|---|---|
| Price | $12.18 | $15.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $15.00 | ★ $32.90 |
| AVG Volume (30 Days) | ★ 730.1K | 652.7K |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,409,889,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.20 | $7.98 |
| 52 Week High | $13.64 | $20.50 |
Technical Indicators
Market Signals| Indicator | WTTR | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 51.38 |
| Support Level | $11.33 | $15.50 |
| Resistance Level | $12.26 | $16.48 |
| Average True Range (ATR) | 0.46 | 0.94 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 56.83 | 18.61 |
Price Performance
Historical ComparisonAbout WTTR Select Water Solutions Inc.
Select Water Solutions Inc provides sustainable water and chemical solutions to the energy industry. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. Its reportable segments are Water Services, Water Infrastructure and Chemical Technologies. It generates the majority of its revenue from Water Services segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.